SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 9, 2006--Hana Biosciences (NASDAQ:HNAB - News), a biopharmaceutical company focused on advancing cancer care, provided an update today on its most advanced drug candidate, Zensana(TM) (ondansetron HCl) Oral Spray. Hana completed pivotal trials for Zensana(TM) in early 2006, which it believes met endpoints sufficient to allow for a New Drug Application (NDA) filing with the Food and Drug Administration under section 505(b)(2) of the Food, Drug and Cosmetic Act, a form of registration that relies on data in previously approved NDAs and published literature. The Company held a voluntary meeting with the FDA yesterday to discuss its planned NDA application. The Company continues to believe it remains on track for a submission in the second quarter of 2006. Subject to approval by the FDA, the company plans to commercially launch Zensana(TM) in the United States in 2007.
